Skip to content
Review

Essential aspects of the prevention of ventilator-associated pneumonia: A State-of-the-Art Review.

Oct 2026 · Intensive & Critical Care Nursing · pp. 104598 · 0 citations · 84 references
Medicine

TL;DR

Prevention of Ventilator-associated pneumonia requires a multimodal approach that integrates organizational support with evidence-based preventive measures and consistent adherence to multidisciplinary prevention bundles remains fundamental for reducing the burden of VAP.

Abstract

Background

Ventilator-associated pneumonia (VAP) is a major cause of morbidity and mortality in the ICU and is associated with high antibiotic consumption and increased healthcare resource utilization.

Objectives

This review provides an updated overview of current strategies for VAP prevention.

Methods

A narrative review of the literature was conducted, including randomized controlled trials, systematic reviews, meta-analyses, and recent international guidelines and position papers on VAP prevention.

Results

Successful VAP prevention depends on both effective implementation strategies and evidence-based clinical interventions. Current preventive measures target the main mechanisms involved in VAP pathogenesis, including prolonged mechanical ventilation, microaspiration, endotracheal tube biofilm formation, and colonization of the aerodigestive tract. Routine preventive measures with the strongest supporting evidence include minimizing the duration of mechanical ventilation and sedation, avoiding unnecessary intubation and re-intubation, semi-recumbent positioning, oral care with toothbrushing rather than chlorhexidine, early enteral nutrition, and the use of structured prevention bundles. Additional interventions, such as subglottic secretion drainage, selective digestive or oropharyngeal decontamination, inhaled antibiotics, early tracheostomy, and post-pyloric feeding, may be beneficial in appropriately selected patients or specific clinical settings. In contrast, some interventions have inconsistent evidence of clinical benefit and are not recommended for routine use.

Conclusions

Preventing VAP requires a multimodal approach that integrates organizational support with evidence-based preventive measures. As new evidence continues to emerge, prevention bundles should be regularly updated to optimize effectiveness while avoiding interventions that are ineffective or potentially harmful. IMPLICATIONS FOR CLINICAL PRACTICE Implementation of VAP prevention strategies should focus on interventions supported by the best available evidence, while tailoring selected strategies to local epidemiology, available resources, and individual patient characteristics. Consistent adherence to multidisciplinary prevention bundles remains fundamental for reducing the burden of VAP.

View source

Similar papers

Review Open access 2026

Epidemiological risks of ventilator-associated pneumonia in the intensive care unit: a narrative literature review

Introduction. Ventilator-associated pneumonia (VAP) remains one of the most common and critical complications in patients receiving artificial lung ventilation (ALV) in intensive care units (ICUs). It is characterized by high morbidity, increased hospital stay and mortality. Assessing the epidemiological risk is an imp...

A. M. Muhametzjanov, T. V. Kajdanek, D. A. Kuzina · 0 citations
Review Open access Sep 2026

BURDEN, RISK FACTORS, AND OUTCOMES OF VENTILATOR-ASSOCIATED PNEUMONIA IN INDIAN INTENSIVE CARE UNITS: A SYSTEMATIC REVIEW

Background: Ventilator-Associated Pneumonia (VAP) is a major healthcare associated infection among patients with artificial airway management and burden of VAP varies among ICUs in India. This systematic review focuses on VAP occurring between the years 2015 to 2025 in India. Reported studies are expected to include da...

S. Patil, Sameer Chandratre · 0 citations
Open access Oct 2026

Primary preventive interventions to reduce ventilator-associated pneumonia in neonatal intensive care units: a meta-analysis.

Bundle-based quality-improvement packages were associated with lower neonatal VAP rates, although heterogeneous bundle composition and non-randomized designs limit causal interpretation, and oral care was also associated with lower VAP odds.

I. Elmakaty, Omar Karen, Rami Kokash et al. · 0 citations
Review Open access Sep 2026

Evidence for the Efficacy and Safety of Tigecycline for the Treatment of Ventilator-Associated Pneumonia in Preterm Infants: A Systematic Review

There is no direct, credible efficacy or safety evidence supporting tigecycline for VAP in preterm infants, and tigecycline warrants consideration only as a last-resort, combination salvage option for culture-confirmed pan- or extensively drug-resistant pathogens.

Gorana Nedin Ranković, D. Krtinić, A. Nikolić et al. · 0 citations
Review 2026

Research Advances on Multidisciplinary Team Collaboration Model for Prevention Ventilator-Associated Pneumonia in ECMO Patients

: Ventilator-associated pneumonia (VAP) is a common and severe complication among patients receiving extracorporeal membrane oxygenation (ECMO) support, increasing the mortality risk and healthcare costs. Traditional single-department management models are inadequate in addressing its complex risk factors. The multidis...

Gen-Zhang Lu, Yu-Ying Hao, Xue-Hui Hu · 0 citations
Review Open access Oct 2026

Low adherence to VAP prevention bundles in LMIC ICUs: gaps and barriers

Abstract Background Ventilator-associated pneumonia (VAP) is a major healthcare-associated infection (HAI) in intensive care units (ICUs), with a high burden in low- and middle-income countries (LMICs). Despite WHO-recommended prevention bundles, adherence remains low, leading to preventable infections and antimicrobia...

T. Sedrakyan, A. Stepanyan, H. Ghazaryan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.